The current and future applications of immunopharmacogenomics

Clinical Advances in Hematology and Oncology

Volumn 13, Issue 12, 2015, Pages 815-817

  Nakamura, Yusuke ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD45 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PERFORIN; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE GRAFT REJECTION; ARTICLE; AUTOIMMUNE DISEASE; DNA SEQUENCE; FOOD ALLERGY; HUMAN; IMMUNOPHARMACOGENOMICS; NEXT GENERATION SEQUENCING; PHARMACOGENOMICS; SOMATIC MUTATION; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOGENETICS; PHARMACOGENETICS; PROCEDURES; TRENDS;

ANIMALS; HUMANS; IMMUNOGENETICS; PHARMACOGENETICS; RECEPTORS, ANTIGEN, B-CELL; RECEPTORS, ANTIGEN, T-CELL;

EID: 84950968618     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Fang H, Yamaguchi R, Liu X, et al. Quantitative T cell repertoire analysis by deep cDNA sequencing of T cell receptor α and β chains using next-generation sequencing (NGS). Oncoimmunology. 2014;3(12):e968467.
2. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015;21(8):914-921.
3. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(1-2):48-61.
4. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-2199.
5. Yew PY, Alachkar H, Yamaguchi R, et al. Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2015;50(9):1227-1234.